Press release
Bronchopulmonary Dysplasia Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Research. Learn more about our innovative pipeline today! @ Bronchopulmonary Dysplasia Pipeline Outlook [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Bronchopulmonary Dysplasia Pipeline Report
* In June 2025, OHB Neonatology Ltd . announced a study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
* DelveInsight's Bronchopulmonary Dysplasia pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Bronchopulmonary Dysplasia treatment.
* The leading Bronchopulmonary Dysplasia Companies such as Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc . and others.
* Promising Bronchopulmonary Dysplasia Pipeline Therapies such as Zelpultide alfa, Inhaled Nitric Oxide, Sildenafil, Pneumostem Registered , Curosurf, OHB-607, Infasurf, Palivizumab and others.
Stay informed about the cutting-edge advancements in Bronchopulmonary Dysplasia treatments. Download for updates and be a part of the revolution in Respiratory Diseases Care @ Bronchopulmonary Dysplasia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bronchopulmonary Dysplasia Emerging Drugs Profile
* AT-100: Airway Therapeutics, Inc
Zelpultide alfa, also known as AT-100, is a novel biologic developed by Airway Therapeutics, Inc. It is a recombinant version of the human surfactant protein D (rhSP-D), engineered to reduce inflammation and infection while modulating the immune response. This therapeutic candidate primarily targets bronchopulmonary dysplasia (BPD). Currently, the drug is in the Phase III stage of its development for the treatment of Bronchopulmonary dysplasia.
* OHB-607: Oak Hill Bio
OHB-607, previously known as TAK-607, is a novel therapeutic candidate developed by Oak Hill Bio, aimed at addressing significant health challenges faced by extremely premature infants. This investigational drug is a recombinant version of insulin-like growth factor 1 (IGF-1), combined with its binding protein IGFBP-3. It is specifically designed to prevent bronchopulmonary dysplasia (BPD). OHB-607 aims to restore IGF-1 levels to those typically present in full-term pregnancies, thereby supporting the normal growth and development of vital organs like the lungs, brain, and eyes. Currently, the drug is in the Phase II stage of its development for the treatment of Bronchopulmonary dysplasia.
The Bronchopulmonary Dysplasia Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Bronchopulmonary Dysplasia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchopulmonary Dysplasia Treatment.
* Bronchopulmonary Dysplasia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Bronchopulmonary Dysplasia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchopulmonary Dysplasia market.
Learn more about Bronchopulmonary Dysplasia Drugs opportunities in our groundbreaking Bronchopulmonary Dysplasia research and development projects @ Bronchopulmonary Dysplasia Unmet Needs [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bronchopulmonary Dysplasia Companies
Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc . and others.
Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Bronchopulmonary Dysplasia Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Bronchopulmonary Dysplasia treatment by visiting our website. Stay informed about how we're transforming the future of Respiratory Disease @ Bronchopulmonary Dysplasia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Bronchopulmonary Dysplasia Pipeline Report
* Coverage- Global
* Bronchopulmonary Dysplasia Companies- Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc . and others.
* Bronchopulmonary Dysplasia Pipeline Therapies- Zelpultide alfa, Inhaled Nitric Oxide, Sildenafil, Pneumostem Registered , Curosurf, OHB-607, Infasurf, Palivizumab and others.
* Bronchopulmonary Dysplasia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bronchopulmonary Dysplasia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Bronchopulmonary Dysplasia Pipeline on our website @ Bronchopulmonary Dysplasia Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Bronchopulmonary Dysplasia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Bronchopulmonary Dysplasia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* AT-100: Airway Therapeutics, Inc
* Mid Stage Products (Phase II)
* OHB-607: Oak Hill Bio
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Bronchopulmonary Dysplasia Key Companies
* Bronchopulmonary Dysplasia Key Products
* Bronchopulmonary Dysplasia- Unmet Needs
* Bronchopulmonary Dysplasia- Market Drivers and Barriers
* Bronchopulmonary Dysplasia- Future Perspectives and Conclusion
* Bronchopulmonary Dysplasia Analyst Views
* Bronchopulmonary Dysplasia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchopulmonary-dysplasia-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bronchopulmonary Dysplasia Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4103592 • Views: …
More Releases from ABNewswire
Cell and Gene Therapies in Rare Disorders Treatment Market 2034: Clinical Trials …
Cell and Gene Therapies in Rare Disorders Companies in the market include - Pfizer, Sangamo Therapeutics, Orchard Therapeutics/ SR-Tiget, Novartis, TVAX Biomedical, Aivita Biomedical, RHEACELL GmbH & Co, Capricor Therapeutics, and others.
(Albany, USA) Cell and Gene Therapies in Rare Disorders Market Summary
The cell and gene therapy market for rare disorders in the 7MM was valued at nearly USD 2 billion in 2023 and is projected to grow substantially by 2034.…
Chronic Hepatitis B Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals …
In 2024, the US led the Chronic Hepatitis B market among the 7MM, followed by Japan (~USD 160M). In the EU4 and UK, Germany topped at ~USD 65M. Pipeline drugs like Daplusiran, Imdusiran, and others are set to boost market growth through 2034. Numerous promising therapies under investigation signal a bright outlook, with future approvals expected to significantly transform the treatment landscape amid rising global healthcare spending.
(Albany, USA) DelveInsight's "Chronic…
Renal Cell Carcinoma Pipeline Appears Robust With 70+ Key Pharma Companies Activ …
DelveInsight's, "Renal Cell Carcinoma Pipeline Insight 2025" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive…
Epilepsy Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working …
DelveInsight's, "Epilepsy Pipeline Insight, 2025" report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epilepsy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Epilepsy pipeline products in this space.
Explore our latest breakthroughs in Epilepsy Research. Learn more…
More Releases for Bronchopulmonary
Global Bronchopulmonary Dysplasia Treatment Market Status and Outlook (2015-2025 …
The research study presented here is an intelligent take on the global Bronchopulmonary Dysplasia Treatment market that explains important aspects such as competition, segmentation, and regional growth in great detail. Accuracy and preciseness are two of the key features of the report that reflect its authenticity. The authors of the report have focused on SWOT analysis, Porter’s Five Forces analysis, and PESTLE analysis of the global Bronchopulmonary Dysplasia Treatment market. In addition,…
Global Bronchopulmonary Dysplasia Treatment Industry Research Analysis by 2020- …
This report also researches and evaluates the impact of Covid-19 outbreak on the Bronchopulmonary Dysplasia Treatment industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Bronchopulmonary Dysplasia Treatment and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Global Bronchopulmonary Dysplasia Treatment Market Overview:
GLOBAL INFO RESEARCH has evaluated the global Bronchopulmonary Dysplasia Treatment market in its latest research report. The research report,…
Bronchopulmonary Dysplasia Treatment Market: Growth and Sales Forecast 2017 - 20 …
Bronchopulmonary dysplasia, a type of chronic lung disorder, affects newborns, mostly premature and infants. Lungs and bronchi are damaged at the neonatal phase which causes destruction of tiny air sacs known as alveoli. Babies are not born with the disease. The condition is developed when premature infants need aid to breathe for a longer period, leading to inflammation and lung scarring. Infants with this disease exhibit signs and symptoms such…
Bronchopulmonary Dysplasia Treatment Market to See Incredible Growth During 2027
Bronchopulmonary dysplasia is a chronic respiratory disease, which is most commonly occurs in premature infants and who received supplemental oxygen or mechanical ventilation. It is also called as respiratory distress syndrome. In addition, bronchopulmonary dysplasia can also occur in infants who experience abnormal lung development or had pre-birth antenatal infection. Most of the infants recover from bronchopulmonary dysplasia, however, some of those have continued lung function and structure abnormalities during…
Bronchopulmonary Dysplasia Treatment Market to Discern Steadfast Expansion Durin …
Bronchopulmonary dysplasia is a chronic respiratory disease, which is most commonly occurs in premature infants and who received supplemental oxygen or mechanical ventilation. It is also called as respiratory distress syndrome. In addition, bronchopulmonary dysplasia can also occur in infants who experience abnormal lung development or had pre-birth antenatal infection. Most of the infants recover from bronchopulmonary dysplasia, however, some of those have continued lung function and structure abnormalities during…
Bronchopulmonary Dysplasia Treatment Market to observe high growth by 2027
Bronchopulmonary dysplasia is a chronic respiratory disease, which is most commonly occurs in premature infants and who received supplemental oxygen or mechanical ventilation. It is also called as respiratory distress syndrome. In addition, bronchopulmonary dysplasia can also occur in infants who experience abnormal lung development or had pre-birth antenatal infection. Most of the infants recover from bronchopulmonary dysplasia, however, some of those have continued lung function and structure abnormalities during…
